Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Changchun GeneScience Pharmaceutical is the lead sponsor of 49 current clinical trials in our China register. 27 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Nano-crystalline Megestrol Acetate, GenSci134 and Recombinant Human Growth Hormone. The most-studied condition is Safety.

ClinicalTrials.gov trials by status

Recruiting2755%
Not yet open1633%
Active, closed612%

Trials by phase

Phase 12449%
Phase 3816%
Phase 2714%
Phase 1/236%
Observational36%
Phase 424%
Not applicable24%

Clinical trials sponsored by Changchun GeneScience Pharmaceutical

49 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors NCT07251166 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2025-12	China
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics NCT07260500 · ClinicalTrials.gov ↗ · Short Stature Children Born Small for Gestational Age (SGA) Drug: PEG-rhGH	Phase 2	Recruiting	2025-11	China
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434 · ClinicalTrials.gov ↗ · Solid Tumors Harboring a TP53 Y220C Mutation	Phase 1	Recruiting	2025-06	China
A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults NCT07473570 · ClinicalTrials.gov ↗ · Healthy Adults Drug: GS3-007a	Phase 1	Recruiting	2026-01	China
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors NCT06772415 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	2025-01	China
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease NCT06569758 · ClinicalTrials.gov ↗ · Safety, Tolerability, GenSci098 Drug: GenSci098	Phase 1	Recruiting	2024-09	China
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia NCT07243379 · ClinicalTrials.gov ↗ · Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia, Multicenter Observational Study Drug: Nanocrystalline Megestrol Acetate	Phase 4	Recruiting	2025-09	China
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. NCT05925452 · ClinicalTrials.gov ↗ · Active Systemic Juvenile Idiopathic Arthritis	Not applicable	Recruiting	2023-12	China
A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets NCT07124221 · ClinicalTrials.gov ↗ · Hyperprolactinemia	Phase 3	Recruiting	2025-09	China
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors. NCT07407504 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated	Phase 1	Recruiting	2026-04	China
A Study of GensSci098 in Subjects With Graves' Disease NCT07286656 · ClinicalTrials.gov ↗ · Safety, Tolerability, GenSci098 Drug: GenSci098	Phase 1	Recruiting	2025-11	China
Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome NCT07691125 · ClinicalTrials.gov ↗ · Short Bowel Syndrome (SBS) in Adults Drug: RhGH	Phase 4	Recruiting	2024-07	China
GenSci143 in Participants With Advanced Solid Tumors NCT07252414 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2025-12	China
Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD NCT07423533 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis Drugs: Adalimumab, GenSci120	Phase 2	Recruiting	2026-04	China
GenSci139 in Patients With Advanced Solid Tumors NCT07230977 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2025-11	China
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. NCT07366866 · ClinicalTrials.gov ↗ · Autoimmune Disease	Phase 1	Recruiting	2026-03	China
A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis. NCT07547995 · ClinicalTrials.gov ↗ · Uveitis	Phase 2	Recruiting	2026-06	China
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors NCT06940102 · ClinicalTrials.gov ↗ · Cachexia, Digestive System Cancer, Gastric Cancer Drug: Nano-crystalline Megestrol Acetate	Observational	Recruiting	2025-03	China
GenSci144 Tablets Phase I Clinical Trial NCT07685210 · ClinicalTrials.gov ↗ · Phenylketonuria	Phase 1	Recruiting	2026-06	China
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China. NCT07040930 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis Drug: GenSci120	Phase 1	Recruiting	2025-08	China
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease NCT06189495 · ClinicalTrials.gov ↗ · Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)	Phase 2	Recruiting	2023-12	China
Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer NCT07150663 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Nano-crystalline Megestrol Acetate	Phase 3	Recruiting	2025-08	China
A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) NCT07016802 · ClinicalTrials.gov ↗ · Safety, Tolerability, Adult Growth Hormone Deficiency Drugs: GenSci134, Norditropin, Recombinant Human Growth Hormone	Phase 1	Recruiting	2025-06	China
Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue NCT06830018 · ClinicalTrials.gov ↗ · Cancer-related Fatigue， Gastric Cancer，Colorectal Cancer，Nano-crystalline Megestrol Acetate，Megestrol Acetate，First-line Treatment Drug: Nano-crystalline Megestrol Acetate	Not applicable	Recruiting	2025-01	China
A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain NCT06963177 · ClinicalTrials.gov ↗ · Endometriosis-related Pain	Phase 2	Recruiting	2025-05	China
A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) NCT07264595 · ClinicalTrials.gov ↗ · Pediatric Growth Hormone Deficiency Drugs: GS3-007a, RhGH	Phase 1/2	Recruiting	2026-01	China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants NCT07476586 · ClinicalTrials.gov ↗ · Healthy Volunteers	Phase 1	Recruiting	2026-04	China
A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) NCT07450001 · ClinicalTrials.gov ↗ · Pediatric Growth Hormone Deficiency Drugs: GenSci134, Norditropin, Recombinant Human Growth Hormone	Phase 1/2	Not yet open	2026-03	China
Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery. NCT06772428 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors	Phase 3	Not yet open	2025-01	China
A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) NCT07450053 · ClinicalTrials.gov ↗ · Idiopathic Short Stature Drugs: GenSci134, Recombinant Human Growth Hormone	Phase 1/2	Not yet open	2026-03	China
Phase 1 Clinical Study of GenSci164 Injection NCT07790783 · ClinicalTrials.gov ↗ · Healthy Adult Trial Participants	Phase 1	Not yet open	2026-08	China
A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women NCT07302035 · ClinicalTrials.gov ↗ · Bacterial Vaginosis Drug: GenSci142	Phase 1	Not yet open	2025-12	China
GS1-144 in Participants With Hepatic Impairment and Healthy Female NCT07491289 · ClinicalTrials.gov ↗ · Hepatic Impairment and Healthy Female	Phase 1	Not yet open	2026-04	China
Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy NCT07130617 · ClinicalTrials.gov ↗ · Efficacy, Safety, Megestrol Acetate Drug: Megestrol Acetate	Phase 1	Not yet open	2025-09	China
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma NCT07356037 · ClinicalTrials.gov ↗ · Cachexia, Hepatocellular Carcinoma Drug: Nanocrystalline Megestrol Acetate	Phase 3	Not yet open	2026-01	China
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase NCT06961201 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy Drug: Nano-crystalline Megestrol Acetate	Phase 3	Not yet open	2025-05	China
Phase 1 Clinical Study of GenSci155 Injection in Healthy Adults NCT07638800 · ClinicalTrials.gov ↗ · Healthy Adult Trial Participants	Phase 1	Not yet open	2026-07	China
A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations NCT06840691 · ClinicalTrials.gov ↗ · Pediatric Growth Hormone Deficiency (PGHD)	Phase 1	Not yet open	2025-05	China
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis NCT06961188 · ClinicalTrials.gov ↗ · Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy Drug: Nano-crystalline Megestrol Acetate	Phase 3	Not yet open	2025-06	China
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion NCT07817615 · ClinicalTrials.gov ↗ · Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)	Phase 1	Not yet open	2026-09	China
To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection NCT06561594 · ClinicalTrials.gov ↗ · Idiopathic Hypogonadotropic Hypogonadism	Phase 3	Not yet open	2024-09	China
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) NCT07663838 · ClinicalTrials.gov ↗ · Randomized, Open-label, Safety Drug: GenSci142	Phase 1	Not yet open	2026-06	China
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART) NCT07553728 · ClinicalTrials.gov ↗ · Infertility	Observational	Not yet open	2026-05	China
Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference NCT06321107 · ClinicalTrials.gov ↗ · Infertility	Observational	Active, closed	2024-03	China
A Study on Bioequivalence of Cabergoline Tablets in Human Body NCT07008417 · ClinicalTrials.gov ↗ · Hyperprolactinemia	Phase 1	Active, closed	2025-06	China
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature NCT02375620 · ClinicalTrials.gov ↗ · Short Stature Children Born Small for Gestational Age (SGA)	Phase 2	Active, closed	2015-04	China
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature NCT03255694 · ClinicalTrials.gov ↗ · Dwarfism	Phase 2	Active, closed	2017-05	China
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. NCT06449027 · ClinicalTrials.gov ↗ · Breast Cancer Subjects	Phase 3	Active, closed	2024-08	China
A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female Participants NCT07537231 · ClinicalTrials.gov ↗ · Healthy Postmenopausal Women, Absorption, Metabolism	Phase 1	Active, closed	2026-04	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Changchun GeneScience Pharmaceutical trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Nano-crystalline Megestrol Acetate5 GenSci1343 Recombinant Human Growth Hormone3 GS3-007a2 GenSci0982 GenSci1202 GenSci1422 Nanocrystalline Megestrol Acetate2 Norditropin2 RhGH2 Adalimumab1 Megestrol Acetate1 PEG-rhGH1

Conditions in Changchun GeneScience Pharmaceutical trials

60 conditions

Safety5Tolerability4Advanced Solid Tumors3Short Stature Children Born Small for Gestational Age (SGA)2Pediatric Growth Hormone Deficiency2Healthy Adult Trial Participants2GenSci0982Infertility2Hyperprolactinemia2Rheumatoid Arthritis2Cachexia2Solid Tumors Harboring a TP53 Y220C Mutation1Healthy Adults1Advanced Solid Tumor1Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors1Idiopathic Short Stature1Thyroid Eye Disease (TED)1Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia1Multicenter Observational Study1Active Systemic Juvenile Idiopathic Arthritis1Bacterial Vaginosis1Hepatic Impairment and Healthy Female1Efficacy1Megestrol Acetate1

By trial register

Register	Trials	Recruiting
Clinical trials in China	49	27

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Safety

Sponsor	Trials
XellSmart Bio-Pharmaceutical (Suzhou)	2
Sichuan Huiyu Pharmaceutical	2
Dr. Ram Manohar Lohia Hospital	1

Sponsors with the most current trials registered for this condition.

Questions about Changchun GeneScience Pharmaceutical trials

How many clinical trials does Changchun GeneScience Pharmaceutical sponsor?

Changchun GeneScience Pharmaceutical is the lead sponsor of 49 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Changchun GeneScience Pharmaceutical trials recruiting?

Yes. 27 of its 49 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Changchun GeneScience Pharmaceutical testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Nano-crystalline Megestrol Acetate (5), GenSci134 (3), Recombinant Human Growth Hormone (3), GS3-007a (2) and GenSci098 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Changchun GeneScience Pharmaceutical clinical trials